Latest Intellectual Property News

Recce Pharmaceuticals has secured a key patent in Hong Kong for its synthetic anti-infectives, reinforcing its intellectual property footprint in Asia and supporting its clinical and commercial ambitions in the region.

Race Oncology has received a $2.8 million Australian R&D tax refund for FY2025, with further overseas R&D rebates expected, bolstering its clinical development of innovative cancer therapies.

Hancock & Gore is rebranding as Schoolblazer Limited following its acquisition of Trutex, consolidating its global school uniform operations and targeting over $200 million in revenue by FY27.

Patrys Limited has expanded its clinical pipeline by acquiring Reliis Pty Ltd, gaining a proprietary injectable formulation of Quetiapine aimed at the large and underserved delirium market. This strategic move balances Patrys’ portfolio with a near-term pharmaceutical asset alongside its biologics program.

Audeara Limited has secured a $1.22 million R&D tax incentive refund for FY25, strengthening its financial position by repaying debt and retaining non-dilutive funding to fuel ongoing product development.

White Energy Company Limited has launched a 5-for-12 partially underwritten entitlement offer at $0.027 per share, aiming to raise approximately $3.5 million to fund mineral exploration and corporate needs. Major shareholders and directors have committed to participate, while the offer excludes ineligible shareholders and related parties.

First Graphene has locked in a 12-month exclusive global license to develop and sell graphene-enhanced carbon paste, a breakthrough material already boosting solar cell efficiency and cutting costs.

MCS Services Limited has agreed to sell the core assets of its Highways Traffic subsidiary to Altus Traffic for $1.4 million, pending shareholder approval. The deal marks a strategic step to streamline operations following previous divestments.

Mesoblast Limited forecasts a significant jump in quarterly revenue, driven by strong sales of its FDA-approved cell therapy Ryoncil. The company’s latest update highlights robust growth and ongoing expansion in inflammatory disease treatments.

Acrux Ltd reported a remarkable surge in licensing revenue from its topical generics portfolio alongside a strategic pivot towards innovative drug delivery R&D at its 2025 Annual General Meeting.

Sea Forest Limited launches a $20.5 million IPO on the ASX to scale production and commercialisation of SeaFeed™, a scientifically validated livestock feed additive that cuts methane emissions by up to 80% while boosting productivity.

Alterity Therapeutics announces significant board changes, including the retirement of founding chairman Geoffrey Kempler and appointment of CEO Dr David Stamler as Managing Director, aligning leadership with its Phase 3 clinical ambitions.